Key Dates

Related Announcements

PA-20-208 - Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Optional)

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

This Notice informs the research community of the following change to Funding Opportunity Announcement (FOA) PA-20-208, "Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Optional)".

Section III. Eligibility Information
Currently Reads: 

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Revised to Read: 

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Note that by the time of award, the applicant must be a citizen or a non-citizen national of the United States or have been lawfully admitted for permanent residence (i.e., possess a currently valid Permanent Resident Card USCIS Form I-551, or other legal verification of such status). Furthermore, at the time of award the applicant must have completed all institutional requirements to enter the dissertation stage of their research program. Multiple PD/PI applications are not allowed.

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Aria Davis Crump, Sc.D.
National Institute on Drug Abuse
Telephone: 301-435-0881
Email: [email protected]